Insights Archive
Filter by:
April 3, 2024
Coffee with ClearScript Hot Topic: GLP-1s, losing weight or losing money?
GLP-1s are a hot topic in health plans due to their high-price tag and coverage complexity. Following up on ClearScript’s recent GLP-1 webinar, this podcast will answer some new questions and provide additional updates about this drug class.
April 3, 2024
Rezdiffra (resmetirom)
On March 14, 2024, drug manufacturer Madrigal Pharmaceuticals announced the approval of Rezdiffra™, a new, first in class oral therapy for nonalcoholic steatohepatitis (NASH). This disease, which impacts an estimated 6-8 million people in the U.S., is underdiagnosed and if left untreated, it can cause serious liver complications. Read more about this approval and its implications.
April 3, 2024
Understanding Biosimilar Basics
With Humira® biosimilars expected to have a significant impact in 2024, some ClearScript clients are asking for more information. Here we provide the biosimilar basics and what their increasing presence in the marketplace means to the pharmacy benefit.
March 27, 2024
How will the rise of BIOSIMILARS affect your pharmacy benefit plan?
ClearScript’s Clinical Account Executives, Bryan Milbert, PharmD, and Nicole Christian, PharmD, provide a factual presentation on biosimilars’ history, outlook, and how these products could bend your cost curve including perspectives from plan sponsors, members, and prescribers.
January 11, 2024
Navigating 2024: Three topics shaping the pharmacy benefit
As we reflect on the developments of 2023 and set our sights on 2024, the pharmacy benefit landscape is undergoing significant transformations. Read on to learn what ClearScript is watching in this evolving and complex field to stay ahead of changes that will impact the pharmacy benefit.
January 11, 2024
New Drug Spotlight: Zepbound
On November 8, 2023, Eli Lilly announced the approval of the newest weight loss drug Zepbound, a much-anticipated formulation of tirzepatide in the high-profile GLP-1 agonist medications class. Used along with reduced calorie diet and exercise, studies have shown Zepbound can lead to significant weight loss.
October 30, 2023
Losing money or losing weight? How the new GLP-1 drugs are affecting your benefit plan
ClearScript’s Vice President of Clinical Operations, Yalda Olcott, PharmD, presents an educational look at how GLP-1 drugs are driving plan spend including their indications, benefits, industry insight, and strategies for navigating these drugs in your benefit plan.
October 2, 2023
New Drug Spotlight: Arexvy, Abrysvo, and Beyfortus
In 2023, the U.S. Food & Drug Administration (FDA) approved three new vaccines for the prevention of Respiratory Syncytial Virus (RSV). RSV is a highly contagious, common respiratory virus that typically causes mild cold-like symptoms. However, it can cause serious illness in older adults and infants.
September 29, 2023
Insulin Update
Amidst growing public and government attention on insulin affordability, what do plan sponsors need to know as they plan coverage strategies in 2024 and beyond?